Eyenovia Inc
NASDAQ:EYEN
Eyenovia Inc
Cash from Operating Activities
Eyenovia Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Eyenovia Inc
NASDAQ:EYEN
|
Cash from Operating Activities
-$23.8m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is Eyenovia Inc's Cash from Operating Activities?
Cash from Operating Activities
-23.8m
USD
Based on the financial report for Dec 31, 2023, Eyenovia Inc's Cash from Operating Activities amounts to -23.8m USD.
What is Eyenovia Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-13%
Over the last year, the Cash from Operating Activities growth was 5%. The average annual Cash from Operating Activities growth rates for Eyenovia Inc have been -55% over the past three years , -13% over the past five years .